Abstract
Objective: Burning mouth syndrome (BMS) and atypical odontalgia (AO) are examples of somatic symptom disorders with predominant pain around the orofacial region. Neuroinflammation is thought to play a role in the mechanisms, but few studies have been conducted. We aimed to better understand the role of neuroinflammation in the pathophysiology and treatment of BMS/AO. Methods: Plasma levels of 28 neuroinflammation-related molecules were determined in 44 controls and 48 BMS/AO patients both pretreatment and 12-week post-treatment with duloxetine. Results: Baseline plasma levels of interleukin (IL)-1β (p <.0001), IL-1 receptor antagonist (p <.001), IL-6 (p <.0001), macrophage inflammatory protein-1β (p <.0001), and platelet-derived growth factor-bb (.04) were significantly higher in patients than in controls. Plasma levels of granulocyte macrophage colony stimulating factor were significantly higher in patients than in controls (p <.001) and decreased with treatment (.009). Plasma levels of eotaxin, monocyte chemoattractant protein-1, and vascular endothelial growth factor decreased significantly with treatment (p <.001,.022, and.029, respectively). Conclusions: Inflammatory mechanisms may be involved in the pathophysiology and/or treatment response of somatic symptom disorders with predominant pain around the orofacial region.
| Original language | English |
|---|---|
| Article number | e2698 |
| Journal | Human Psychopharmacology |
| Volume | 34 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 01-07-2019 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Neurology
- Clinical Neurology
- Psychiatry and Mental health
- Pharmacology (medical)
Cite this
}
Effect of antidepressant treatment on plasma levels of neuroinflammation-associated molecules in patients with somatic symptom disorder with predominant pain around the orofacial region. / Miyauchi, Tomoya; Tokura, Tatsuya; Kimura, Hiroyuki; Ito, Mikiko; Umemura, Eri; Sato (Boku), Aiji; Nagashima, Wataru; Tonoike, Takashi; Yamamoto, Yasuko; Saito, Kuniaki; Kurita, Kenichi; Ozaki, Norio.
In: Human Psychopharmacology, Vol. 34, No. 4, e2698, 01.07.2019.Research output: Contribution to journal › Article
TY - JOUR
T1 - Effect of antidepressant treatment on plasma levels of neuroinflammation-associated molecules in patients with somatic symptom disorder with predominant pain around the orofacial region
AU - Miyauchi, Tomoya
AU - Tokura, Tatsuya
AU - Kimura, Hiroyuki
AU - Ito, Mikiko
AU - Umemura, Eri
AU - Sato (Boku), Aiji
AU - Nagashima, Wataru
AU - Tonoike, Takashi
AU - Yamamoto, Yasuko
AU - Saito, Kuniaki
AU - Kurita, Kenichi
AU - Ozaki, Norio
PY - 2019/7/1
Y1 - 2019/7/1
N2 - Objective: Burning mouth syndrome (BMS) and atypical odontalgia (AO) are examples of somatic symptom disorders with predominant pain around the orofacial region. Neuroinflammation is thought to play a role in the mechanisms, but few studies have been conducted. We aimed to better understand the role of neuroinflammation in the pathophysiology and treatment of BMS/AO. Methods: Plasma levels of 28 neuroinflammation-related molecules were determined in 44 controls and 48 BMS/AO patients both pretreatment and 12-week post-treatment with duloxetine. Results: Baseline plasma levels of interleukin (IL)-1β (p <.0001), IL-1 receptor antagonist (p <.001), IL-6 (p <.0001), macrophage inflammatory protein-1β (p <.0001), and platelet-derived growth factor-bb (.04) were significantly higher in patients than in controls. Plasma levels of granulocyte macrophage colony stimulating factor were significantly higher in patients than in controls (p <.001) and decreased with treatment (.009). Plasma levels of eotaxin, monocyte chemoattractant protein-1, and vascular endothelial growth factor decreased significantly with treatment (p <.001,.022, and.029, respectively). Conclusions: Inflammatory mechanisms may be involved in the pathophysiology and/or treatment response of somatic symptom disorders with predominant pain around the orofacial region.
AB - Objective: Burning mouth syndrome (BMS) and atypical odontalgia (AO) are examples of somatic symptom disorders with predominant pain around the orofacial region. Neuroinflammation is thought to play a role in the mechanisms, but few studies have been conducted. We aimed to better understand the role of neuroinflammation in the pathophysiology and treatment of BMS/AO. Methods: Plasma levels of 28 neuroinflammation-related molecules were determined in 44 controls and 48 BMS/AO patients both pretreatment and 12-week post-treatment with duloxetine. Results: Baseline plasma levels of interleukin (IL)-1β (p <.0001), IL-1 receptor antagonist (p <.001), IL-6 (p <.0001), macrophage inflammatory protein-1β (p <.0001), and platelet-derived growth factor-bb (.04) were significantly higher in patients than in controls. Plasma levels of granulocyte macrophage colony stimulating factor were significantly higher in patients than in controls (p <.001) and decreased with treatment (.009). Plasma levels of eotaxin, monocyte chemoattractant protein-1, and vascular endothelial growth factor decreased significantly with treatment (p <.001,.022, and.029, respectively). Conclusions: Inflammatory mechanisms may be involved in the pathophysiology and/or treatment response of somatic symptom disorders with predominant pain around the orofacial region.
UR - http://www.scopus.com/inward/record.url?scp=85066912556&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066912556&partnerID=8YFLogxK
U2 - 10.1002/hup.2698
DO - 10.1002/hup.2698
M3 - Article
C2 - 31125145
AN - SCOPUS:85066912556
VL - 34
JO - Human Psychopharmacology
JF - Human Psychopharmacology
SN - 0885-6222
IS - 4
M1 - e2698
ER -